Compare Campbell Soup Co. (CPB) vs Zoetis Inc (ZTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Campbell Soup Co. vs Zoetis Inc — how do they compare? Campbell Soup Co. trades at $19.1 (market cap $5.78B), while Zoetis Inc trades at $74.18 (market cap $30.20B). The key difference: Zoetis Inc is far larger — about 5.2× Campbell Soup Co.'s market cap, and Campbell Soup Co. pays the higher dividend (5.16%). Which is the better fit depends on your goals — on Pluang, investors hold Campbell Soup Co. for 98 Days and Zoetis Inc for 70 Days on average.
| CPB | ZTS | |
|---|---|---|
Market Cap | $5.78B | $30.20B |
Volume | 11,705,427 | 6,175,327 |
Sector | Consumer Staples | Health |
52-Week High | $31.66 | $147.53 |
52-Week Low | $18.90 | $69.09 |
Typical Hold Time | 98 Days | 70 Days |
Enterprise Value | $12.83B | $37.76B |
Dividend Yield | 5.16% | 2.9% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Campbell's stock trades at $18.90, down 0.53% with bearish technical signals. The company reported mixed Q2 2026 earnings, beating expectations but showing margin pressure. Recent dividend cut of 36% and workforce reduction signal turnaround efforts amid declining profitability. Valuation appears reasonable with P/E of 14.79 and P/S of 0.6, but revenue growth remains challenged.
The outlook remains cautious with analyst consensus leaning heavily toward Hold (58.62%). While cost-saving initiatives and balance sheet improvements provide some support, persistent margin compression and competitive pressures create headwinds. The stock trades near the lower end of analyst targets ($18-22), offering limited upside potential amid ongoing operational challenges.
Zoetis (ZTS) trades at $71.55, showing modest daily gains of 0.32% amid a challenging market environment. The stock faces bearish technical signals with mixed earnings performance, having beaten estimates in Q2 2026 but missing in Q1. Despite recent headwinds in U.S. companion animal sales, the company maintains strong profitability with 71.67% gross margins and 27.69% net income margins. Analyst consensus remains positive with a $87.33 price target, though technical indicators suggest near-term pressure with support at $70-$71.
Zoetis presents a compelling value opportunity with attractive valuation multiples (P/E 11.92, EV/EBITDA 9.4) and robust fundamentals, though near-term risks include competitive pressures in pet medications and weakening U.S. veterinary clinic traffic. The company's international and livestock segments show resilience, supporting long-term growth potential despite current market skepticism.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Campbell Soup Co.
With a history that dates back around 150 years, Campbell Soup is now a leading manufacturer and marketer of branded convenience food products, most notably soup. The firm's product assortment includes well-known brands like Campbell's, Pace, Prego, Swanson, V8, and Pepperidge Farm. Following the sale of its international snacking operations, which wrapped in calendar 2019, the firm derives nearly all of its sales from its home turf. Campbell has made a handful of acquisitions to reshape its product mix the past few years, including the tie-up with Snyder's-Lance (completed in March 2018), which enhances its exposure to the faster-growing on-trend snack food aisle, complementing its Pepperidge Farm lineup.
Read more on CPB →About Zoetis Inc
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →
